These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31010254)

  • 1. Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro.
    Makarević J; Rutz J; Juengel E; Maxeiner S; Tsaur I; Chun FK; Bereiter-Hahn J; Blaheta RA
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31010254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells.
    Juengel E; Najafi R; Rutz J; Maxeiner S; Makarevic J; Roos F; Tsaur I; Haferkamp A; Blaheta RA
    Oncotarget; 2017 Dec; 8(66):110016-110028. PubMed ID: 29299126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells.
    Makarević J; Tawanaie N; Juengel E; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    J Cell Mol Med; 2014 Jul; 18(7):1460-6. PubMed ID: 24779401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression.
    Makarević J; Rutz J; Juengel E; Maxeiner S; Mani J; Vallo S; Tsaur I; Roos F; Chun FK; Blaheta RA
    Cells; 2018 Sep; 7(9):. PubMed ID: 30200497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro.
    Juengel E; Natsheh I; Najafi R; Rutz J; Tsaur I; Haferkamp A; Chun FK; Blaheta RA
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31167517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.
    Vallo S; Xi W; Hudak L; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
    Anticancer Drugs; 2011 Nov; 22(10):1002-9. PubMed ID: 21822119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.
    Wedel S; Hudak L; Seibel JM; Makarević J; Juengel E; Tsaur I; Waaga-Gasser A; Haferkamp A; Blaheta RA
    BMC Cancer; 2011 Aug; 11():375. PubMed ID: 21867506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.
    Juengel E; Nowaz S; Makarevi J; Natsheh I; Werner I; Nelson K; Reiter M; Tsaur I; Mani J; Harder S; Bartsch G; Haferkamp A; Blaheta RA
    Mol Cancer; 2014 Jun; 13():152. PubMed ID: 24935000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulforaphane as an adjunctive to everolimus counteracts everolimus resistance in renal cancer cell lines.
    Juengel E; Euler S; Maxeiner S; Rutz J; Justin S; Roos F; Khoder W; Nelson K; Bechstein WO; Blaheta RA
    Phytomedicine; 2017 Apr; 27():1-7. PubMed ID: 28314474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.
    Wedel S; Hudak L; Seibel JM; Juengel E; Oppermann E; Haferkamp A; Blaheta RA
    Prostate; 2011 May; 71(7):722-35. PubMed ID: 20954195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
    Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
    Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
    Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
    Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic acid induces autophagy by suppressing the Akt/mTOR pathway in human prostate cancer cells.
    Xia Q; Zheng Y; Jiang W; Huang Z; Wang M; Rodriguez R; Jin X
    Oncol Lett; 2016 Sep; 12(3):1826-1832. PubMed ID: 27588130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
    Thelen P; Krahn L; Bremmer F; Strauss A; Brehm R; Loertzer H
    Int J Mol Med; 2013 Feb; 31(2):339-46. PubMed ID: 23292124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.
    Tsaur I; Hudak L; Makarević J; Juengel E; Mani J; Borgmann H; Gust KM; Schilling D; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
    J Cell Mol Med; 2015 Aug; 19(8):1795-804. PubMed ID: 25808196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro.
    Makarević J; Tsaur I; Juengel E; Borgmann H; Nelson K; Thomas C; Bartsch G; Haferkamp A; Blaheta RA
    Life Sci; 2016 Feb; 147():137-42. PubMed ID: 26827990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal.
    Wei M; Mao S; Lu G; Li L; Lan X; Huang Z; Chen Y; Zhao M; Zhao Y; Xia Q
    BMC Cancer; 2018 Apr; 18(1):434. PubMed ID: 29665787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.